文献速递临床试验与 GCP基础与转化研究

间充质前体细胞心肌内注射与晚期心力衰竭患者左心室辅助装置支持成功临时撤机:一项随机临床试验

Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

6个月内成功临时撤机的平均比例MPC组为61%、对照组为58%(RR 1.08,95%CI 0.83-1.41,P=0.55),未达预设的贝叶斯后验概率80%成功阈值。结论认为心肌内注射MPCs未能改善6个月时LVAD成功临时撤机。

要点

  • MPCs增加成功撤机可能性的后验概率为69%,低于预设80%成功阈值。
  • 6个月内成功临时撤机的平均比例MPC组61% vs 对照组58%(RR 1.08,95%CI 0.83-1.41,P=0.55)。
  • 无患者发生主要安全性终点事件;1年死亡率MPC组14.2% vs 对照组15.1%(HR 0.89,95%CI 0.38-2.11,P=0.80)。

核心结论

  • 在晚期心力衰竭患者中,与假注射冷冻保护介质相比,心肌内注射间充质前体细胞未能改善6个月时左心室辅助装置支持的成功临时撤机。
  • 研究结果不支持使用心肌内间充质干细胞促进以临时撤机为衡量指标的心脏恢复。

研究设计与样本

  • 随机2期临床试验,在19个北美中心开展,时间为2015年7月至2017年8月,1年随访于2018年8月结束。
  • 共159例患者,平均年龄56岁,女性11.3%,155例(97.5%)完成1年随访。

主要发现

  • 主要疗效终点为随机化后6个月内3次计划评估中成功临时撤机的比例,MPCs增加成功撤机可能性的后验概率为69%,低于预设80%成功阈值。
  • 6个月内成功临时撤机的平均比例MPC组为61%,对照组为58%(RR 1.08,95%CI 0.83-1.41,P=0.55)。
  • 无患者发生主要安全性终点事件(心肌炎、心肌破裂、肿瘤、过敏反应和免疫致敏)。
  • 报告的10个预设次要终点中9个未达统计学显著;1年死亡率MPC组14.2% vs 对照组15.1%(HR 0.89,95%CI 0.38-2.11,P=0.80)。
  • 严重不良事件发生率MPC组70.9 vs 对照组78.7每100患者月(差值-7.89,95%CI -39.95至24.17,P=0.63),再入院率MPC组0.68 vs 对照组0.75每100患者月(差值-0.07,95%CI -0.41至0.27,P=0.68),均无显著差异。

关键数值与推荐

  • 主要疗效终点成功标准为预设的贝叶斯后验概率80%阈值,实际后验概率为69%。
  • 6个月成功临时撤机平均比例MPC组61% vs 对照组58%(RR 1.08,95%CI 0.83-1.41,P=0.55)。
  • 1年死亡率MPC组14.2% vs 对照组15.1%(HR 0.89,95%CI 0.38-2.11,P=0.80)。

临床怎么用

  • 原文结论指出,研究结果不支持使用心肌内间充质干细胞促进以左心室辅助装置临时撤机为衡量指标的心脏恢复。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Left ventricular assist device (LVAD) therapy improves myocardial function, but few patients recover sufficiently for explant, which has focused attention on stem cells to augment cardiac recovery. OBJECTIVE: To assess efficacy and adverse effects of intramyocardial injections of mesenchymal precursor cells (MPCs) during LVAD implant. DESIGN, SETTING, AND PARTICIPANTS: A randomized phase 2 clinical trial involving patients with advanced heart failure, undergoing LVAD implant, at 19 North American centers (July 2015-August 2017). The 1-year follow-up ended August 2018. INTERVENTIONS: Intramyocardial injections of 150 million allogeneic MPCs or cryoprotective medium as a sham treatment in a 2:1 ratio (n = 106 vs n = 53). MAIN OUTCOMES AND MEASURES: The primary efficacy end point was the proportion of successful temporary weans (of 3 planned assessments) from LVAD support within 6 months of randomization. This end point was assessed using a Bayesian analysis with a predefined threshold of a posterior probability of 80% to indicate success. The 1-year primary safety end point was the incidence of intervention-related adverse events (myocarditis, myocardial rupture, neoplasm, hypersensitivity reactions, and immune sensitization). Secondary end points included readmissions and adverse events at 6 months and 1-year survival. RESULTS: Of 159 patients (mean age, 56 years; 11.3% women), 155 (97.5%) completed 1-year of follow-up. The posterior probability that MPCs increased the likelihood of successful weaning was 69%; below the predefined threshold for success. The mean proportion of successful temporary weaning from LVAD support over 6 months was 61% in the MPC group and 58% in the control group (rate ratio [RR], 1.08; 95% CI, 0.83-1.41; P = .55). No patient experienced a primary safety end point. Of 10 prespecified secondary end points reported, 9 did not reach statistical significance. One-year mortality was not significantly different between the MPC group and the control group (14.2% vs 15.1%; hazard ratio [HR], 0.89; 95%, CI, 0.38-2.11; P = .80). The rate of serious adverse events was not significantly different between groups (70.9 vs 78.7 per 100 patient-months; difference, -7.89; 95% CI, -39.95 to 24.17; P = .63) nor was the rate of readmissions (0.68 vs 0.75 per 100 patient-months; difference, -0.07; 95% CI, -0.41 to 0.27; P = .68). CONCLUSIONS AND RELEVANCE: Among patients with advanced heart failure, intramyocardial injections of mesenchymal precursor cells, compared with injections of a cryoprotective medium as sham treatment, did not improve successful temporary weaning from left ventricular assist device support at 6 months. The findings do not support the use of intramyocardial mesenchymal stem cells to promote cardiac recovery as measured by temporary weaning from device support. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02362646.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Yau TM, Pagani FD, Mancini DM, et al. Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial. JAMA. 2019. PMID: 30912838. doi:10.1001/jama.2019.2341

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。